Literature DB >> 27546845

Neuroendocrine Tumors.

Ron Basuroy1, Raj Srirajaskanthan1, John K Ramage2.   

Abstract

Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which have commonly been mistaken for other disorders initially. The diagnostic workup to characterize tumor behaviour and prognosis focuses on histologic, anatomic, and functional imaging assessments. Several therapeutic options exist for patients ranging from curative and debulking surgery through to liver-directed therapies and systemic treatments. Multimodal therapies are often required over the patient's disease history. The management paradigm can be complex but should be focused on curative resections and then on controlling symptoms and limiting disease progression. There are several new systemic therapies that have completed phase 3 studies with new compounds being studied in phase 2. Genetic and epigenetic markers may lead to a new era of personalised therapy in the future. Crown
Copyright © 2016. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoid; Diagnostics; Multimodal; Neuroendocrine; Therapy; Tumor

Mesh:

Substances:

Year:  2016        PMID: 27546845     DOI: 10.1016/j.gtc.2016.04.007

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  10 in total

1.  Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.

Authors:  J Zou; Q Li; F Kou; Y Zhu; M Lu; J Li; Z Lu; L Shen
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  Does Seratonin in the intestines make you happy?

Authors:  Atilla Bektaş; Harun Erdal; Meltem Ulusoy; I Tayfun Uzbay
Journal:  Turk J Gastroenterol       Date:  2020-10       Impact factor: 1.852

3.  Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases.

Authors:  Fengju Chen; Yiqun Zhang; Don L Gibbons; Benjamin Deneen; David J Kwiatkowski; Michael Ittmann; Chad J Creighton
Journal:  Clin Cancer Res       Date:  2018-02-09       Impact factor: 12.531

Review 4.  Diagnosis and Surgical Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: A Literature Review.

Authors:  Shuzo Kohno
Journal:  Cancer Diagn Progn       Date:  2022-03-03

5.  Double contrast-enhanced ultrasonography of a small intestinal neuroendocrine tumor: a case report of a recommendable imaging modality.

Authors:  Jie-Ying Zhao; Hua Zhuang; Yuan Luo; Ming-Gang Su; Mo-Li Xiong; Yu-Ting Wu
Journal:  Precis Clin Med       Date:  2020-04-17

6.  Prescription patterns of long-acting somatostatin analogues.

Authors:  Jorge Enrique Machado-Alba; Manuel Enrique Machado-Duque
Journal:  SAGE Open Med       Date:  2017-03-09

7.  Delays and routes to diagnosis of neuroendocrine tumours.

Authors:  Ron Basuroy; Catherine Bouvier; John Keith Ramage; Maia Sissons; Raj Srirajaskanthan
Journal:  BMC Cancer       Date:  2018-11-16       Impact factor: 4.430

8.  Risk Factors Associated with the Development of Metastases in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis.

Authors:  Shuzo Kohno; Masahiro Ikegami; Toru Ikegami; Hiroaki Aoki; Masaichi Ogawa; Fumiaki Yano; Ken Eto
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

9.  Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

Authors:  Martyn E Caplin
Journal:  EJC Suppl       Date:  2021-11-09

10.  68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study.

Authors:  Marcelo Cavicchioli; Almir Galvão Vieira Bitencourt; Eduardo Nóbrega Pereira Lima
Journal:  Radiol Bras       Date:  2022 Jan-Feb
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.